Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study
Background Ixekizumab (anti‐IL17A) is effective as treatment for moderate‐to‐severe plaque psoriasis, but real‐life data on effectiveness and safety are currently very limited. Objective To evaluate the efficacy and safety of ixekizumab in a cohort of real‐life plaque psoriasis patients. Methods Ret...
Gespeichert in:
| Veröffentlicht in: | Journal of the European Academy of Dermatology and Venereology 2019-03, Vol.33 (3), p.553-559 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 559 |
|---|---|
| container_issue | 3 |
| container_start_page | 553 |
| container_title | Journal of the European Academy of Dermatology and Venereology |
| container_volume | 33 |
| creator | Deza, G. Notario, J. Lopez‐Ferrer, A. Vilarrasa, E. Ferran, M. del Alcazar, E. Carrascosa, J.M. Corral, M. Salleras, M. Ribera, M. Puig, L. Pujol, R. M. Vidal, D. Gallardo, F. |
| description | Background
Ixekizumab (anti‐IL17A) is effective as treatment for moderate‐to‐severe plaque psoriasis, but real‐life data on effectiveness and safety are currently very limited.
Objective
To evaluate the efficacy and safety of ixekizumab in a cohort of real‐life plaque psoriasis patients.
Methods
Retrospective chart review of 100 patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab at seven Spanish dermatological centres.
Results
According to the as observed analysis, the percentage of patients achieving a 75% and 90% of reduction from the baseline score of Psoriasis Area and Severity Index (PASI) was 87.5%–50.0% at week 12–16; 88.3%–58.4% at week 24 and 82.9%–58.5% at week 52, respectively. The mean ± standard deviation (SD) score of PASI at baseline was 12.9 ± 9.2, and it declined rapidly after ixekizumab administration to 1.9 ± 4.0 (P |
| doi_str_mv | 10.1111/jdv.15288 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2120206021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2120206021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3258-1976d99701548a4865c4bfa367db5624fe68f5089d41f1fbd55c3f15b1fcf7203</originalsourceid><addsrcrecordid>eNp1kLtOHDEUhq0IlF1IirwAckmKWWzP2GOniyDhIiSaJO3I44vkxXOJ7QGGAuUReEaeBMNu6DjN0ZG-8-nXD8AXjFY4z9Fa36wwJZx_AEtcMV6UiJc7YIkEYYUQVCzAXoxrhBDGlH8EixKVuGa1WIKH894lJz0MJk4-RThY6O7MtbufOtlCY61TUs1Q9hpGaU2aoeszLP3Tv8fbIXgNRy__TgaOcQhORhfhKJMzfYrfoIRdljqVr2DyVwpDHI1K7sbAmCY9fwK7VvpoPm_3Pvj988ev47Pi8ur0_Pj7ZaFKQnmBRc20EDXCtOKy4oyqqrWyZLVuKSOVNYxbirjQFbbYtppSVVpMW2yVrQkq98HhxjuGIYeNqelcVMZ72Zthig3BBBHEEMEZ_bpBVQ4bg7HNGFwnw9xg1LzU3eS6m9e6M3uw1U5tZ_Qb-b_fDBxtgFvnzfy-qbk4-bNRPgOtgY0h</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2120206021</pqid></control><display><type>article</type><title>Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Deza, G. ; Notario, J. ; Lopez‐Ferrer, A. ; Vilarrasa, E. ; Ferran, M. ; del Alcazar, E. ; Carrascosa, J.M. ; Corral, M. ; Salleras, M. ; Ribera, M. ; Puig, L. ; Pujol, R. M. ; Vidal, D. ; Gallardo, F.</creator><creatorcontrib>Deza, G. ; Notario, J. ; Lopez‐Ferrer, A. ; Vilarrasa, E. ; Ferran, M. ; del Alcazar, E. ; Carrascosa, J.M. ; Corral, M. ; Salleras, M. ; Ribera, M. ; Puig, L. ; Pujol, R. M. ; Vidal, D. ; Gallardo, F.</creatorcontrib><description>Background
Ixekizumab (anti‐IL17A) is effective as treatment for moderate‐to‐severe plaque psoriasis, but real‐life data on effectiveness and safety are currently very limited.
Objective
To evaluate the efficacy and safety of ixekizumab in a cohort of real‐life plaque psoriasis patients.
Methods
Retrospective chart review of 100 patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab at seven Spanish dermatological centres.
Results
According to the as observed analysis, the percentage of patients achieving a 75% and 90% of reduction from the baseline score of Psoriasis Area and Severity Index (PASI) was 87.5%–50.0% at week 12–16; 88.3%–58.4% at week 24 and 82.9%–58.5% at week 52, respectively. The mean ± standard deviation (SD) score of PASI at baseline was 12.9 ± 9.2, and it declined rapidly after ixekizumab administration to 1.9 ± 4.0 (P < 0.001) at week 12–16 and was maintained at 1.7 ± 4.1 and 1.8 ± 2.9 at week 24 and 52, respectively. Ixekizumab response was not affected by clinical variables like body mass index, disease duration or the presence of psoriatic arthritis. However, the bio‐naive group showed significantly higher PASI 75 response rate at week 12–16 compared to patients previously exposed to biologic agents (P = 0.037). Twenty‐six (26%) patients experienced adverse events (AEs) during the follow‐up period, being most of them of mild‐to‐moderate intensity. The most common AE was local reaction at the site of injection (14/26; 53.8%). At the end of the observational period, 15 (15%) patients discontinued ixekizumab treatment due to limited clinical improvement (n = 11), adverse events (n = 3) or lost to follow‐up (n = 1) within a mean ± SD time of 6.0 ± 3.9 months.
Conclusion
The present study illustrates the initial experience with ixekizumab in real‐world clinical practice confirming its usefulness and safety in the management of plaque psoriasis patients.</description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.15288</identifier><identifier>PMID: 30317679</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Biological Products - therapeutic use ; Dermatologic Agents - adverse effects ; Dermatologic Agents - therapeutic use ; Female ; Humans ; Injection Site Reaction - etiology ; Male ; Middle Aged ; Psoriasis - drug therapy ; Retreatment ; Retrospective Studies ; Severity of Illness Index</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2019-03, Vol.33 (3), p.553-559</ispartof><rights>2018 European Academy of Dermatology and Venereology</rights><rights>2018 European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3258-1976d99701548a4865c4bfa367db5624fe68f5089d41f1fbd55c3f15b1fcf7203</citedby><cites>FETCH-LOGICAL-c3258-1976d99701548a4865c4bfa367db5624fe68f5089d41f1fbd55c3f15b1fcf7203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjdv.15288$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjdv.15288$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30317679$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deza, G.</creatorcontrib><creatorcontrib>Notario, J.</creatorcontrib><creatorcontrib>Lopez‐Ferrer, A.</creatorcontrib><creatorcontrib>Vilarrasa, E.</creatorcontrib><creatorcontrib>Ferran, M.</creatorcontrib><creatorcontrib>del Alcazar, E.</creatorcontrib><creatorcontrib>Carrascosa, J.M.</creatorcontrib><creatorcontrib>Corral, M.</creatorcontrib><creatorcontrib>Salleras, M.</creatorcontrib><creatorcontrib>Ribera, M.</creatorcontrib><creatorcontrib>Puig, L.</creatorcontrib><creatorcontrib>Pujol, R. M.</creatorcontrib><creatorcontrib>Vidal, D.</creatorcontrib><creatorcontrib>Gallardo, F.</creatorcontrib><title>Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Background
Ixekizumab (anti‐IL17A) is effective as treatment for moderate‐to‐severe plaque psoriasis, but real‐life data on effectiveness and safety are currently very limited.
Objective
To evaluate the efficacy and safety of ixekizumab in a cohort of real‐life plaque psoriasis patients.
Methods
Retrospective chart review of 100 patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab at seven Spanish dermatological centres.
Results
According to the as observed analysis, the percentage of patients achieving a 75% and 90% of reduction from the baseline score of Psoriasis Area and Severity Index (PASI) was 87.5%–50.0% at week 12–16; 88.3%–58.4% at week 24 and 82.9%–58.5% at week 52, respectively. The mean ± standard deviation (SD) score of PASI at baseline was 12.9 ± 9.2, and it declined rapidly after ixekizumab administration to 1.9 ± 4.0 (P < 0.001) at week 12–16 and was maintained at 1.7 ± 4.1 and 1.8 ± 2.9 at week 24 and 52, respectively. Ixekizumab response was not affected by clinical variables like body mass index, disease duration or the presence of psoriatic arthritis. However, the bio‐naive group showed significantly higher PASI 75 response rate at week 12–16 compared to patients previously exposed to biologic agents (P = 0.037). Twenty‐six (26%) patients experienced adverse events (AEs) during the follow‐up period, being most of them of mild‐to‐moderate intensity. The most common AE was local reaction at the site of injection (14/26; 53.8%). At the end of the observational period, 15 (15%) patients discontinued ixekizumab treatment due to limited clinical improvement (n = 11), adverse events (n = 3) or lost to follow‐up (n = 1) within a mean ± SD time of 6.0 ± 3.9 months.
Conclusion
The present study illustrates the initial experience with ixekizumab in real‐world clinical practice confirming its usefulness and safety in the management of plaque psoriasis patients.</description><subject>Adult</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Biological Products - therapeutic use</subject><subject>Dermatologic Agents - adverse effects</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Injection Site Reaction - etiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Psoriasis - drug therapy</subject><subject>Retreatment</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kLtOHDEUhq0IlF1IirwAckmKWWzP2GOniyDhIiSaJO3I44vkxXOJ7QGGAuUReEaeBMNu6DjN0ZG-8-nXD8AXjFY4z9Fa36wwJZx_AEtcMV6UiJc7YIkEYYUQVCzAXoxrhBDGlH8EixKVuGa1WIKH894lJz0MJk4-RThY6O7MtbufOtlCY61TUs1Q9hpGaU2aoeszLP3Tv8fbIXgNRy__TgaOcQhORhfhKJMzfYrfoIRdljqVr2DyVwpDHI1K7sbAmCY9fwK7VvpoPm_3Pvj988ev47Pi8ur0_Pj7ZaFKQnmBRc20EDXCtOKy4oyqqrWyZLVuKSOVNYxbirjQFbbYtppSVVpMW2yVrQkq98HhxjuGIYeNqelcVMZ72Zthig3BBBHEEMEZ_bpBVQ4bg7HNGFwnw9xg1LzU3eS6m9e6M3uw1U5tZ_Qb-b_fDBxtgFvnzfy-qbk4-bNRPgOtgY0h</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Deza, G.</creator><creator>Notario, J.</creator><creator>Lopez‐Ferrer, A.</creator><creator>Vilarrasa, E.</creator><creator>Ferran, M.</creator><creator>del Alcazar, E.</creator><creator>Carrascosa, J.M.</creator><creator>Corral, M.</creator><creator>Salleras, M.</creator><creator>Ribera, M.</creator><creator>Puig, L.</creator><creator>Pujol, R. M.</creator><creator>Vidal, D.</creator><creator>Gallardo, F.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201903</creationdate><title>Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study</title><author>Deza, G. ; Notario, J. ; Lopez‐Ferrer, A. ; Vilarrasa, E. ; Ferran, M. ; del Alcazar, E. ; Carrascosa, J.M. ; Corral, M. ; Salleras, M. ; Ribera, M. ; Puig, L. ; Pujol, R. M. ; Vidal, D. ; Gallardo, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3258-1976d99701548a4865c4bfa367db5624fe68f5089d41f1fbd55c3f15b1fcf7203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Biological Products - therapeutic use</topic><topic>Dermatologic Agents - adverse effects</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Injection Site Reaction - etiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Psoriasis - drug therapy</topic><topic>Retreatment</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deza, G.</creatorcontrib><creatorcontrib>Notario, J.</creatorcontrib><creatorcontrib>Lopez‐Ferrer, A.</creatorcontrib><creatorcontrib>Vilarrasa, E.</creatorcontrib><creatorcontrib>Ferran, M.</creatorcontrib><creatorcontrib>del Alcazar, E.</creatorcontrib><creatorcontrib>Carrascosa, J.M.</creatorcontrib><creatorcontrib>Corral, M.</creatorcontrib><creatorcontrib>Salleras, M.</creatorcontrib><creatorcontrib>Ribera, M.</creatorcontrib><creatorcontrib>Puig, L.</creatorcontrib><creatorcontrib>Pujol, R. M.</creatorcontrib><creatorcontrib>Vidal, D.</creatorcontrib><creatorcontrib>Gallardo, F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deza, G.</au><au>Notario, J.</au><au>Lopez‐Ferrer, A.</au><au>Vilarrasa, E.</au><au>Ferran, M.</au><au>del Alcazar, E.</au><au>Carrascosa, J.M.</au><au>Corral, M.</au><au>Salleras, M.</au><au>Ribera, M.</au><au>Puig, L.</au><au>Pujol, R. M.</au><au>Vidal, D.</au><au>Gallardo, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2019-03</date><risdate>2019</risdate><volume>33</volume><issue>3</issue><spage>553</spage><epage>559</epage><pages>553-559</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><abstract>Background
Ixekizumab (anti‐IL17A) is effective as treatment for moderate‐to‐severe plaque psoriasis, but real‐life data on effectiveness and safety are currently very limited.
Objective
To evaluate the efficacy and safety of ixekizumab in a cohort of real‐life plaque psoriasis patients.
Methods
Retrospective chart review of 100 patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab at seven Spanish dermatological centres.
Results
According to the as observed analysis, the percentage of patients achieving a 75% and 90% of reduction from the baseline score of Psoriasis Area and Severity Index (PASI) was 87.5%–50.0% at week 12–16; 88.3%–58.4% at week 24 and 82.9%–58.5% at week 52, respectively. The mean ± standard deviation (SD) score of PASI at baseline was 12.9 ± 9.2, and it declined rapidly after ixekizumab administration to 1.9 ± 4.0 (P < 0.001) at week 12–16 and was maintained at 1.7 ± 4.1 and 1.8 ± 2.9 at week 24 and 52, respectively. Ixekizumab response was not affected by clinical variables like body mass index, disease duration or the presence of psoriatic arthritis. However, the bio‐naive group showed significantly higher PASI 75 response rate at week 12–16 compared to patients previously exposed to biologic agents (P = 0.037). Twenty‐six (26%) patients experienced adverse events (AEs) during the follow‐up period, being most of them of mild‐to‐moderate intensity. The most common AE was local reaction at the site of injection (14/26; 53.8%). At the end of the observational period, 15 (15%) patients discontinued ixekizumab treatment due to limited clinical improvement (n = 11), adverse events (n = 3) or lost to follow‐up (n = 1) within a mean ± SD time of 6.0 ± 3.9 months.
Conclusion
The present study illustrates the initial experience with ixekizumab in real‐world clinical practice confirming its usefulness and safety in the management of plaque psoriasis patients.</abstract><cop>England</cop><pmid>30317679</pmid><doi>10.1111/jdv.15288</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0926-9959 |
| ispartof | Journal of the European Academy of Dermatology and Venereology, 2019-03, Vol.33 (3), p.553-559 |
| issn | 0926-9959 1468-3083 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2120206021 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Biological Products - therapeutic use Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Female Humans Injection Site Reaction - etiology Male Middle Aged Psoriasis - drug therapy Retreatment Retrospective Studies Severity of Illness Index |
| title | Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T16%3A37%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Initial%20results%20of%20ixekizumab%20efficacy%20and%20safety%20in%20real%E2%80%90world%20plaque%20psoriasis%20patients:%20a%20multicentre%20retrospective%20study&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Deza,%20G.&rft.date=2019-03&rft.volume=33&rft.issue=3&rft.spage=553&rft.epage=559&rft.pages=553-559&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.15288&rft_dat=%3Cproquest_cross%3E2120206021%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2120206021&rft_id=info:pmid/30317679&rfr_iscdi=true |